Blocking effects of siRNA on VEGF expression in human colorectal cancer cells

Figure 1 Immunohistochemical staining of colorectal carcinoma (CRC) tissue sections and immunocytochemical staining of HCT116 cells. The expression of vascular endothelial cell growth factor (VEGF) (SP × 100, A), Fms-like tyrosine kinase 1 (FLT-1) (SP × 100, B) and fetal liver kinase 1 (FLK-1) (SP × 100, C) is positive in the CRC sections and strongly positive in HCT116 cells (SP × 400, D).

Figure 2 Expression of VEGF in HCT116 cells after VEGF-small interfering RNA (siRNA) transfection. 1: Normal control group; 2: Lipofectamine 2000 control group; 3: Mismatched control group; 4: VEGF-siRNA group; 5: 5-FU group. β-actin: Internal control.

Figure 3 Inhibition of HCT116 cell proliferation at different time points after VEGF-siRNA transfection (%).

Figure 4 Apoptosis of HCT116 cells measured by flow cytometry (FCM). The percentage of the pre-G0-G1 population (peak) is shown for each histogram. The peak indicates the apoptosis rate of the cells. N: Normal control group; M: Mismatched group; V: VEGF-siRNA group; F: 5-FU group.